---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-011579"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-27T00:03:50.464444+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma reports FY2021 net loss $12.4M; cash $70.7M; RADR platform surpasses 18B data points

## Summary
- Cash and marketable securities $70.7M at Dec 31, 2021, up from $19.2M at year-end 2020; share repurchase authorized up to $7M.
- FY2021 net loss $12.4M ($1.13/share) vs $5.9M ($1.37/share) in FY2020; R&D expense rose to $7.6M.
- RADR AI platform grew from 1.2B to over 18B data points during 2021; target of 25B by end 2022.
- LP-300 Phase 2 Harmonic trial for never-smoker NSCLC expected to launch in 2022; LP-184 multiple Phase 1 trials in 2022.
- LP-184 received Orphan Drug Designations for pancreatic cancer, GBM, ATRT; Rare Pediatric Disease Designation for ATRT.

## SEC filing metadata
- accession: 0001213900-22-011579
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000121390022011579/0001213900-22-011579-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000121390022011579/ea156639-8k_lantern.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-011579
- JSON: https://secwatch.observer/filing/0001213900-22-011579.json
- Plain text: https://secwatch.observer/filing/0001213900-22-011579.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.